Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: loading-up on spiking stocks could be detrimental to your portfolio

September 19, 2018 7:50am

Key word – rotation, it’s a circular cycle of momentum oriented equities come with a lot of hazards and partial exits are risk-reducing vehicles

It’s a strategy to pound some pricings, maybe not today but, it is coming!

Pre-open indications: targets of opportunity 13 perceived overbought

What is fair game as defined by legitimate equities to trade?

RMi provides a pre-market synopsis for the U.S. trading day.

U.S. stock index futures are shaky

Dow futures are DOWN -0.02% (-5 points) and NASDAQ futures are DOWN -0.10% (-8 points)

U.S. stock index futures are flip-flopping ahead of Wednesday's open, lifted by positive sentiment seen in markets overseas.

European markets are trading up as investors appear to brush off escalating trade tensions between the U.S. and China.

Asia markets mostly rose as investors shrugged- escalation of trade tensions.

Data docket: at 8:30 a.m. ET, housing starts, building permits and the U.S. International Transactions report are due. Mortgage applications are due out at 7 a.m. ET.

Today’s indications:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating in Wednesday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is NOT indicating in Wednesday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Wednesday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a -0.04% DOWNSIDE in Wednesday’s pre-open

Henry’omics:

Markets were given a slight boost as stocks in both Asia and Europe posted gains during their Wednesday sessions.

People are always asking me, what’s the most difficult job or position I been in? I always say it’s the job I’m doing at the moment. There are days that I really touch a nerve in connecting with sector “participants”.

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors for insight into sector vulnerabilities and strengths.

I always return to my basis of writing or action; that warning analysis is many times hard to accept!

Warning is an intangible, an abstraction, a deduction, a perception, a belief. It is a product of REASONING or of logic, a hypothesis whose validity can be neither confirmed nor refuted until it is too late.”

There is barely ANY news, good, bad or indifferent …thus, there are times, when the likelihood of MY conclusions inescapable!

I always want to know what happened PRIOR to what might happen today – it sets a tone of consequence:

From Tuesday’s night’s newsletter: “a strong dose of value. The sector pops along with the NASDAQ (+0.76%) and the IBB (+1.12%) with extremely low volumes. As I had stated, ““Our” universe should make some better headway after yesterday’s drubbing!” The real issue is what caused Monday’s downdrafts? The weighting of the rebound after a severe sell-offs reinforces, there is a further concern – trading is the foundation of sentiment!”

The iShares NASDAQ Biotechnology (IBB): history lesson

Tuesday closed up +1.12%
Monday closed down -1.32%
Friday was down -0.51%
Thursday was up +0.74%
Wednesday was up +0.05%
For a five session aggregate of +0.02% -I’d trade carefully!

In 11 sessions in September (so far) – there were 6 negative closes and 5 positive close;

In 21 August sessions – 6 had negative and 15 positive closes

Of the 45 companies covered on Monday; 7 downside equities finished in a range of -0.53% (ATHX) to -1.77% (OSIR) while 36 upside equity oscillated from +0.33% (MESO) to +10.55% (SLDB) with 2 flat closes (AST and GBT).

Companies in my headlights – It’s your decision; I provide the idea and context:

I sticking with the issue of reflex action and overbought – if NOT today but, by Monday:

Targets of opportunity …

CRSP, NTLA and EDIT

BSTG, RARE, AXGN and ADRO

CLBS, FATE, MDXG, QURE and VCEL,

And VSTM

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.